IRVINE, Calif.–(BUSINESS WIRE)–Ellipse Technologies, Inc., a global medical device company, announced today that it has received FDA 510(k) clearance to market a second, shorter 70 mm actuator as part of the MAGEC (MAGnetic Expansion Control) Spinal Bracing and Distraction System. During the same week, the company marked its 100th MAGEC surgery since its limited market introduction in the United States in April.
“Furthermore, as shown by several multicenter studies, distraction-based systems have the advantage of providing superior growth potential over growth-guided options.”
The MAGEC system provides a unique alternative to the traditional treatment regimen using growing rods which require repetitive invasive lengthening surgeries for early onset scoliosis care. Also, MAGEC presents a compelling clinical option compared to “growth-guided” systems that require fusions at multiple levels which limit the patient’s ultimate growth potential. The MAGEC system is the only non-invasive, distraction-based system available worldwide for these young patients.
The addition of the 70 mm actuator implant enables broader application of the MAGEC system for patients with limited spinal space attributed to severe spinal deformities. This device features a 20% reduction in the length of the existing MAGEC 90 mm actuator, providing surgeons better rod contouring capabilities during surgical procedures. It is estimated that this may enable a 15-20% increase in the number of patients that may benefit from the MAGEC system.
“Pediatric spinal deformity surgeons fully recognize the game-changing benefits of the MAGEC system in eliminating the emotional and painful treatment associated with traditional growing rods,” stated Behrooz Akbarnia, M.D., clinical professor of Orthopedic Surgery at the University of California, San Diego. “Furthermore, as shown by several multicenter studies, distraction-based systems have the advantage of providing superior growth potential over growth-guided options.”
News of the FDA clearance and the enthusiastic adoption of MAGEC at initial centers in the United States follows the recent published guidance of the United Kingdom’s NICE organization which broadly approved its use based upon both its efficacy and cost-effectiveness.
To date, the MAGEC system has been used by more than 200 surgeons in 27 countries in more than 1500 surgical procedures.
About Ellipse Technologies
Ellipse Technologies, Inc. is a privately held medical device company located in Irvine, California. The company is dedicated to the design, development, and commercialization of its evolving proprietary technology platform for orthopedic and spinal applications. This technology enables precisely controlled, non-invasive post-operative adjustment of implants allowing surgeons to better address a range of clinical needs. In addition to the MAGEC® system, Ellipse markets the PRECICE® limb lengthening system. Ellipse is developing additional products to significantly improve clinical outcomes in a variety of applications through its collaboration with surgeon thought leaders. For more information, visit www.ellipse-tech.com.
Contacts
for Ellipse Technologies, Inc.
Paul Williams, 310-569-0023
paul@medialinecommunications.com
